Peptide Comparison Tool
Compare peptides side-by-side to understand their mechanisms, FDA status, dosing protocols, costs, and clinical evidence — all in one place.
Editorial independence
We do not receive compensation from any peptide manufacturer or pharmacy.
Evidence-based
Data sourced from published clinical trials and FDA filings.
Patient-first
Built to help you have informed conversations with your provider.
About this comparison tool
Peptide therapy is a rapidly evolving field with varying levels of clinical evidence. This tool helps you understand the key differences between popular therapeutic peptides so you can have more informed discussions with your healthcare provider.
FDA status matters:Some peptides (like semaglutide and tirzepatide) are FDA-approved with robust Phase 3 trial data. Others (like BPC-157 and TB-500) are research compounds with primarily preclinical evidence. We clearly label each peptide's regulatory status.
Cost context: Pricing reflects 2026 averages from brand manufacturers and compounding pharmacies. Your actual cost may vary by provider, location, and dosing protocol.
Evidence quality:We rate evidence from “Limited” (primarily preclinical or observational) to “Strong” (multiple Phase 3 RCTs or FDA approval with clinical data).